Didier Smadja

Prof. Didier Smadja


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Revue Neurologique
Verified
Journal Article
Closed access
SOS. Olindo
S. Olindo
GMG. Marnat
G. Marnat
NCN. Chausson
N. Chausson
CTC. Turpinat
C. Turpinat
DSDidier Smadja
Didier Smadja
NGN. Gaillard
N. Gaillard

9 May 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
HVHélène Viruega
Hélène Viruega
CICarole Imbernon
Carole Imbernon
NCNicolas Chausson
Nicolas Chausson
TATony Altarcha
Tony Altarcha
MAManvel Aghasaryan
Manvel Aghasaryan
Manuel GaviriaManuel Gaviria
Manuel Gaviria
Background: Stroke is a high burden illness and the second leading cause of worldwide disability with generally poor recovery rates. Robust benefits of hippotherapy, a novel neurorehabilitation approach, in functional recovery following various severe neurological disabling conditions has been shown. In the present study, we will analyze the effect of a hippotherapy program on the outcome of post-stroke patients in the first year post-stroke. Method: A randomized controlled clinical trial on the effectiveness of hippotherapy (4 weeks/18 weeks hippotherapy/conventional neurorehabilitation) versus conventional neurorehabilitation alone (22 weeks) will be conducted over 48 weeks. In the treated group, one-hour daily hippotherapy sessions will be exclusively conducted during the hippotherapy’s cycles, alternated with periods of conventional neurorehabilitation. A test battery will measure both the functional and psychological outcomes. The primary endpoint will be the patient’s functional independence. The secondary endpoints will measure the sensorimotor function, autonomy, and quality of life, as well as the caregivers’ quality of life. Results and conclusion: Individual brain connectome, life history and personality construct influence the brain’s functional connectivity and are central to developing optimal tailored neurorehabilitation strategies. According to our current practice, hippotherapy allows the enhancement of substantial neuroplastic changes in the injured brain with significant neurological recovery. The protocol aims to confirm those issues. Trial registration in ClinicalTrials.gov NCT04759326 accessed on 19 February 2021.

1 December 2024 in European Stroke Journal
Verified
Journal Article
Closed access
NCNicolas Chausson
Nicolas Chausson
SOStéphane Olindo
Stéphane Olindo
FLFrançois-Xavier Laborne
François-Xavier Laborne
MAManvel Aghasaryan
Manvel Aghasaryan
PRPauline Renou
Pauline Renou
DSDidier Smadja
Didier Smadja
Introduction: In intracranial medium-vessel occlusions (MeVOs), intravenous thrombolysis (IVT) shows inconsistent effectiveness and endovascular interventions remains unproven. We evaluated a new therapeutic strategy based on a second IVT using tenecteplase for MeVOs without early recanalization post-alteplase. Patients and methods: This retrospective, comparative study included consecutively low bleeding risk MeVO patients treated with alteplase 0.9 mg/kg at two stroke centers. One center used a conventional single-IVT approach; the other applied a dual-IVT strategy, incorporating a 1-h post-alteplase MRI and additional tenecteplase, 0.25 mg/kg, if occlusion persisted. Primary outcomes were 24-h successful recanalization for efficacy and symptomatic intracranial hemorrhage (sICH) for safety. Secondary outcomes included 3-month excellent outcomes (modified Rankin Scale score of 0–1). Comparisons were conducted in the overall cohort and a propensity score-matched subgroup. Results: Among 146 patients in the dual-IVT group, 103 failed to achieve recanalization at 1 h and of these 96 met all eligible criteria and received additional tenecteplase. Successful recanalization at 24 h was higher in the 146 dual-IVT cohort patients than in the 148 single-IVT cohort patients (84% vs 61%, p < 0.0001), with similar sICH rate (3 vs 2, p = 0.68). Dual-IVT strategy was an independent predictor of 24-h successful recanalization (OR, 2.7 [95% CI, 1.52–4.88]; p < 0.001). Dual-IVT cohort patients achieved higher rates of excellent outcome (69% vs 44%, p < 0.0001). Propensity score matching analyses supported all these associations. Conclusion: In this retrospective study, a dual-IVT strategy in selected MeVO patients was associated with higher odds of 24-h recanalization, with no safety concerns. However, potential center-level confounding and biases seriously limit these findings’ interpretation. Trial Registration: ClinicalTrials.gov Identifier: NCT05809921

1 August 2025 in Stroke
Verified
Journal Article
Closed access
PPPauline Poirette
Pauline Poirette
NCNicolas Chausson
Nicolas Chausson
JPJean Papaxanthos
Jean Papaxanthos
MKMaeva Kyheng
Maeva Kyheng
JLJulien Labreuche
Julien Labreuche
CICAROWEB Investigators
CAROWEB Investigators
BACKGROUND: Carotid web is a rare and likely underrecognized cause of ischemic stroke, particularly in young patients. Given the high risk of recurrence, diagnostic delays may have serious consequences. This study aimed to assess the incidence and impact of delayed carotid web diagnosis after a first ischemic event. METHODS: We conducted a retrospective analysis using data from the French ongoing multicenter prospective CAROWEB (Carotid Web registry). We included patients with a first-ever ischemic stroke or transient ischemic attack in the anterior circulation, attributed to an ipsilateral carotid web with no other identifiable cause, between September 2013 and April 2023. Patients with missing data on the date of the first ischemic event or carotid web diagnosis, or with prior stroke history, were excluded. Participants were categorized into early diagnosis (≤30 days) and delayed diagnosis (>30 days) groups. Factors associated with diagnostic delay were investigated through univariable and multivariable analyses. Stroke recurrence was evaluated using Kaplan-Meier survival analysis. RESULTS: Of 280 patients in the registry, 225 met the inclusion criteria. A delayed diagnosis occurred in 57 patients (25.3%). Independent predictors of diagnostic delay included lower initial National Institutes of Health Stroke Scale score (odds ratio, 0.92; P =0.002), stroke occurring before 2019 (odds ratio, 0.19; P <0.001), and the absence of computed tomography angiography in the initial work-up (odds ratio, 0.20; P <0.001). Stroke recurrence was significantly higher in the delayed group (3.6 versus 0.38 per 100 patient-years). After adjusting for the National Institutes of Health Stroke Scale and year of stroke onset, delayed diagnosis was associated with a 5-fold increased risk of recurrence (adjusted hazard ratio, 5.02; P =0.014). CONCLUSIONS: Delayed carotid web diagnosis remains common, especially in minor strokes, in the absence of early computed tomography angiography, and in events before 2019. Such delays are associated with a significantly increased risk of stroke recurrence, highlighting the need for early vascular imaging in ischemic stroke evaluation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04431609.

1 December 2024 in European Stroke Journal
Verified
Journal Article
Closed access
GMGaultier Marnat
Gaultier Marnat
GGGaspard Gerschenfeld
Gaspard Gerschenfeld
SOStephane Olindo
Stephane Olindo
ISIgor Sibon
Igor Sibon
PSPierre Seners
Pierre Seners
GTGuillaume Turc
Guillaume Turc
Background: Despite its increasing use, there are limited data on the risk of intracranial hemorrhage (ICH) after intravenous thrombolysis with tenecteplase in the setting of acute ischemic stroke. Our aim was to investigate the incidence and predictors of ICH after tenecteplase administration. Methods: We reviewed data from the prospective ongoing multicenter TETRIS (Tenecteplase Treatment in Ischemic Stroke) registry. Patients with available day-1 imaging were included in this study. Clinical, imaging and biological variables were collected. Follow-up imaging performed 24 h after IVT was locally reviewed by senior neuroradiologists and neurologists. The incidence of parenchymal hematoma (PH) and any ICH were investigated. Potential predictors of PH and any ICH were assessed in multivariable logistic regressions. Subgroup analyses focusing on patients intended for endovascular treatment were performed. Results: PH and any ICH occurred in 126/1321 (incidence rate: 9.5%, 95% CI 8.1–11.2) and 521/1321 (39.4%, 95% CI 36.8–42.1) patients, respectively. Symptomatic ICH was observed in 77/1321 (5.8%; 95% CI 4.7–7.2). PH occurrence was significantly associated with poorer functional outcomes (p < 0.0001) and death (p < 0.0001) after 3 months. Older age (aOR = 1.03; 95% CI 1.01–1.05), male gender (aOR = 2.07; 95% CI 1.28–3.36), a history of hypertension (aOR = 2.08; 95% CI 1.19–3.62), a higher baseline NIHSS (aOR = 1.07; 95% CI 1.03–1.10) and higher admission blood glucose level (aOR = 1.12; 95% CI 1.05–1.19) were independently associated with PH occurrence. Similar associations were observed in the subgroup of patients intended for endovascular treatment. Conclusion: We quantified the incidence of ICH after IVT with tenecteplase in a real-life prospective registry and determined independent predictors of ICH. These findings allow to identify patients at high risk of ICH.

1 December 2025 in European Stroke Journal
Verified
Journal Article
Closed access
MYMarion Yger
Marion Yger
EJEdouard Januel
Edouard Januel
TCThomas Checkouri
Thomas Checkouri
NCNicolas Chausson
Nicolas Chausson
DSDidier Smadja
Didier Smadja
GGGaspard Gerschenfeld
Gaspard Gerschenfeld
Introduction: A better understanding of sex-related differences remains key to improve stroke care for women. We aimed to assess the differences of prognosis, symptomatic intracranial hemorrhage (sICH) rates and process times between men and women suffering from ischemic stroke. Patients and methods: We performed a sex-based retrospective analysis of the French Tenecteplase Treatment in Stroke multicentric registry from 2015 to 2021. We assessed sex differences in terms of 3-month good neurological outcome (defined as modified Rankin score ⩽ 2 or back to its pre-stroke value), occurrence of sICH and process times with multivariable logistic regression analyses. Results: 1339 consecutive patients (684 women, 655 men) received tenecteplase between 2015 and 2021, among whom 873 underwent thrombectomy. Both groups differed in terms of demographic characteristics, etiology, and unclear onset. In multivariable logistic regression analyses, women and men did not differ in terms of 3-month good neurological outcome (aOR = 0.85 [0.63–1.13]). Women were less likely to have a sICH after tenecteplase (aOR = 0.35 [0.18–0.69]) and more likely to have a stroke of unknown onset (aOR 1.44 [1.07–1.95]), but workflow metrics did not differ once stroke code was triggered. Discussion and conclusion: In our study, we did not find a significant difference between women and men in terms of 3-month good outcome. However, our study size may hinder its detection. Interestingly, we observed that women had a lower rate of sICH after tenecteplase. Women’s workflow metrics were similar to men’s, except for a higher rate of stroke with an unknown onset.